MTPR yields 1000000.00% · ABBV yields 3.06%● Live data
📍 MTPR pulled ahead of the other in Year 1
Combined, MTPR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MTPR + ABBV for your $10,000?
MetaPower International, Inc. operates as a management-consulting and technology company in North America. The company offers Noble Production, a suite of automated processes and attendant services that provide heavy industrial facilities with the tools necessary to guide the evolution of their organization and its culture. It also offers a suite of services to support Noble Production. These services include assessment services that assist clients in determining their performance relative to OSHA's Voluntary Protection Program 1 Safety criteria; culture reform services, including training and consulting services; business process management services comprising Noble Production automated process customization and business process design services; and cause analysis services, including cause analysis training and event investigations for investigating and determining the cause of conditions and incidents. In addition, the company provides consulting services in various areas, including business process management, program design and implementation, process design, procedure development and implementation, business system planning and implementation, corrective action programs, cause analysis, process safety management, and culture change management. Further, it offers training courses in various aspects of position competency, including technical training, performance training, supervision and leadership training, and other skill and knowledge based training. The company was founded in 1996 and is based in Vancouver, Washington.
Full MTPR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.